EUVIMEDEUVIMED entdecken
Crossref

COVID-19 Update: Metformin to Prevent Long Covid?

The Medical Letter on Drugs and Therapeutics · 2023

DOI: 10.58347/tml.2023.1677e ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, 2023. Hauptthemen laut MEDLINE: Metformin, COVID-19.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Results from a double-blind trial suggest that off-label use of the oral antihyperglycemic drug metformin in patients with COVID-19 may decrease the risk of post-acute sequelae of SARS-CoV-2 infection (“long COVID”).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminCOVID-19HumansPost-Acute COVID-19 SyndromeHypoglycemic AgentsSARS-CoV-2Ivermectin

Stichwörter der Autor:innen

COVID-19adverse effectsdosagedrug interactionsefficacyfluvoxamineivermectinmetforminsafety

Substanzen

MetforminHypoglycemic AgentsIvermectin

Zitieren

APA

(2023). COVID-19 Update: Metformin to Prevent Long Covid?. The Medical Letter on Drugs and Therapeutics. https://doi.org/10.58347/tml.2023.1677e

Vancouver

COVID-19 Update: Metformin to Prevent Long Covid?. The Medical Letter on Drugs and Therapeutics. 2023. doi:10.58347/tml.2023.1677e

BibTeX
@article{euvimed2023,
  title = {COVID-19 Update: Metformin to Prevent Long Covid?},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2023},
  doi = {10.58347/tml.2023.1677e}
}
Kostenlos starten →